Evangelisches Krankenhaus Witten gGmbH
- Address
- lock Available on a paid plan
Evangelisches Krankenhaus Witten gGmbH - Cardiovascular and Metabolic Research
Evangelisches Krankenhaus Witten gGmbH is a distinguished clinical research center specializing in cardiovascular and metabolic disorders. The institution demonstrates expertise in conducting advanced pharmaceutical trials for conditions that pose significant risks to cardiovascular health, with a particular focus on innovative therapeutic interventions for complex patient populations.
- Severe Hypertriglyceridemia and lipid metabolism disorders
- Atrial Fibrillation and cardioembolic event prevention
- Novel anticoagulation therapies and cardiovascular risk reduction
The center's research portfolio includes Phase 3 investigations of cutting-edge medications, including studies evaluating olezarsen for managing severe hypertriglyceridemia and milvexian as an alternative anticoagulant for patients with atrial fibrillation. These trials reflect the institution's commitment to advancing treatment options for patients at high risk of stroke, systemic embolism, and metabolic complications, contributing valuable clinical evidence to improve cardiovascular outcomes and patient care standards.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Evangelisches Krankenhaus Witten gGmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Andexanet Alfa | 1 | Unknown | 2023-08-23 | 2023-08-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.